Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2Q Pharma Results Preview: Bristol, AstraZeneca, Roche, Celgene, Bayer, Merck, AbbVie & Sanofi

Executive Summary

PD-1 inhibitor performance and the intense curiosity around AstraZeneca both for its MYSTIC trial and Soriot's faithfulness to the company are key themes at the half-year mark. Eyes are also on commercial performance for Roche's Ocrevus and Merck's anacetrapib for clarity on whether it has a commercial future.

Advertisement

Related Content

More Than CAR-T: Hematologic Oncology Pipeline Offers Rich Menu Of Possible Approvals
Will Soriot Ditch AstraZeneca In Favor Of Teva… And A $20m Bonus?
Keytruda Approval Opens New Routes For Immuno-Oncology
Celgene's Positive Ozanimod Data Puts Focus On MS Commercialization
AstraZeneca's Imfinzi Steals March Into Untapped IO Lung Cancer Territory
Keytruda/Chemo Combo Approval Means Merck Holds Crown, For Now
Rydapt And Alunbrig Approvals Headline Good Week For Targeted Oncologics At US FDA
Bristol's New CSO Lynch Defends Lung Cancer Plans, Proclaims R&D Priorities
Bristol's CheckMate 067 Revives Debate On Rationing Yervoy/Opdivo Combo
Agios, Celgene Target Accelerated Approvals For Precision AML Medicines

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099189

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel